At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GRI GRI BIO INC
Closed 11-25 16:00:00 EST
0.7390
+0.0500
+7.26%
盘后0.7399
+0.0009+0.12%
19:57 EST
High0.7395
Low0.6690
Vol240.47K
Open0.6690
D1 Closing0.6890
Amplitude10.23%
Mkt Cap2.16M
Tradable Cap2.16M
Total Shares2.93M
T/O168.52K
T/O Rate8.24%
Tradable Shares2.92M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Equinix Continues to Expand Sustainability Initiatives with Additional €1.15 Billion in Green Bonds
GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis
GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis
GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that develops as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in La Jolla, California.